Moderna (NASDAQ:MRNA) Issues Earnings Results, Beats Expectations By $0.52 EPS

Moderna (NASDAQ:MRNA) issued its quarterly earnings data on Thursday. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52, Briefing.com reports. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same quarter last year, the company earned $0.19 earnings per share. The firm’s revenue for the quarter was down 91.0% compared to the same quarter last year.

Moderna Stock Down 0.5 %

NASDAQ MRNA traded down $0.59 on Friday, reaching $125.00. 4,513,133 shares of the company were exchanged, compared to its average volume of 3,445,723. The business’s fifty day moving average price is $105.05 and its 200 day moving average price is $94.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 4.03. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $142.79.

Analysts Set New Price Targets

Several brokerages have weighed in on MRNA. Royal Bank of Canada raised their price target on Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. HSBC reiterated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday. Finally, Canaccord Genuity Group boosted their price objective on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $129.55.

Insiders Place Their Bets

In other Moderna news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now owns 8,557 shares of the company’s stock, valued at $809,235.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 139,954 shares of company stock valued at $14,822,576. Insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.